Fulcrum Signs License Deal with Sanofi for Development of Losmapimod in FSHD
Fulcrum Therapeutics has entered into a collaboration and license agreement with Sanofi for the development and commercialization of losmapimod.
Fulcrum Therapeutics | 14/05/2024 | By Aishwarya | 105
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy